^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Triple Negative Breast Cancer
    Drug:Talzenna (talazoparib) (PARP inhibitor) +
    LY294002 (PI3K inhibitor, AKT inhibitor, FAK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cell Signal
    Title:

    Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells

    Published date:
    12/24/2021
    Excerpt:
    Here, we, for the first time, investigated that the combined inhibition of PARP by Talazoparib (TAL) and PI3K by LY294002 synergistically inhibited proliferation of BRCA1 mutant HCC1937 TNBC cells... Our findings revealed that the dual inhibition of PARP and PI3K might represent an effective therapeutic strategy for TNBC and potentially overcome TAL resistance.
    DOI:
    10.1016/j.cellsig.2021.110229